Spectrum Pharma (NASDAQ:SPPI): Cancer Biotech Takeover Target Print E-mail
Tuesday, 30 June 2009 09:46
BioMedReports.com - Spectrum Pharma (NASDAQ:SPPI): Cancer Biotech Takeover TargetSpectrum Pharmaceuticals (Nasdaq: SPPI) has two upcoming dates with regulators in the coming days and months. Here are 17 good reasons why Bayer might seriously consider acquiring Spectrum Pharmaceuticals (Nasdaq: SPPI) at some point in the future. Listed below are 17 ongoing clinical trials for Zevalin.  Each trial is sorted by its corresponding completion date.  Data source: FDA.

 

July 2                Zevalin

 

October 8          Fusilev

Bayer Schering (Bayer) markets Zevalin in Europe and abroad - all countries ex. US.  Bayer received approval for Zevalin as a first-line consolidation therapy on April 28, 2008.  For details, please refer to my recent article here and here.

2009

August

Phase 2

Fludarabine Plus Zevalin . . .

September

Phase 2

Response Study of Zevalin in Patients with DLBCL after 6 cycles of CHOP

December

Phase 3

Study Comparing Zevalin Regimen with NO further treatment in DLBCL

Patients who are in Complete Remission after CHOP-R

 

2010

January

Phase 2

Zevalin in Combination with Z-CHOP in Treating Patients with Stage 2-4 DLBCL

July

Phase 2

Zevalin + Rituxan Maintenance

Sponsor: University of Wisconsin

August

Phase 2

Autologous Stem Cell Transplant with Zevalin + Busulfan

December

Phase 2

Chemo followed by Zevalin for Relapsed Mantle Cell Lymphoma

Sponsor: Dana-Faber Cancer Institute

 

2011

January

Phase 2

Safety of Zevalin,

Sponsor: Bayer Schering

 

2012

January

Phase 2

Zevalin Twice in Aggressive NHL

January

Phase 2

Safety Study to Evaluate Induction & Consolidation Treatment in Mantle Cell Lymphoma

June

Phase 3

Zevalin-BEAM for aggressive lymphoma

Sponsor: Sheba Medical Center

December

Phase 1 / 2

Zevalin with Non Myeloablative Allogeneic Stem Cell Transplant in NHL

 

2013

April

Phase 2

Consolidation Treatment with Zevalin after R-CHOP Induction in

High Risk Patients According to FLIPI with fNHL

 

2014

June

Phase 2

Zevalin-BEAM with Autologous Stem Cell

August

Phase 2

Zevalin & Simultaneous Application of BEAM High Dose Chemo

October

Phase 2

Zevalin First-Line fNHL

Sponsor: Charite University, Berlin, Germany

 

2016

December

Phase 2

R-CHOP in fNHL Patients NOT Previously Treated. Consolidation with Zevalin

versus Maintenance with Rituxan

 

CONCLUSION

Though it is NOT possible to conclude that Bayer will acquire SPPI with any certainty, however, it does seem plausible.

Contributed by Justin M. Hall

Disclosure: Long SPPI




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter